ORKA (Oruka Therapeutics) Ending Cash Position: $49.52 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORKA Oruka Therapeutics Inc ORKA
14 GF Score
Price $92.49
! 3 Warning Signs
View Full Analysis

What is Oruka Therapeutics Ending Cash Position?

Oruka Therapeutics ORKA +0.37% 14 Ending Cash Position is $49.52 Mil as of Mar. 2026. GuruFocus rates ORKA with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Oruka Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $49.52 Mil.

Oruka Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($91.25 Mil) to Dec. 2025 ($46.94 Mil) but then increased from Dec. 2025 ($46.94 Mil) to Mar. 2026 ($49.52 Mil).

Oruka Therapeutics's annual Ending Cash Position stayed the same from . 20 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($46.94 Mil).

Oruka Therapeutics Ending Cash Position Related Terms

Oruka Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Oruka Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics Ending Cash Position Chart

Oruka Therapeutics Annual Data
Trend Dec24 Dec25
Ending Cash Position
0.00 46.94

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only 83.57 65.40 91.25 46.94 49.52
ORKA
14GF Score
Oruka Therapeutics Inc ORKA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oruka Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Oruka Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=61.575+-14.64
=46.94

Oruka Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=46.935+2.585
=49.52

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $49.52 Mil mean?
Oruka Therapeutics (ORKA) has a Ending Cash Position of $49.52 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Oruka Therapeutics and its competitors.
Is Oruka Therapeutics' Ending Cash Position too high?
Oruka Therapeutics' current Ending Cash Position is $49.52 Mil. Overall, Oruka Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' Ending Cash Position compare to DNTH and SRRK?
Oruka Therapeutics' Ending Cash Position of $49.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Oruka Therapeutics and its competitors. Oruka Therapeutics's current Ending Cash Position is $49.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (ORKA) has a current Ending Cash Position of $49.52 Mil. The current Ending Cash Position is $49.52 Mil. Oruka Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Oruka Therapeutics (ORKA), the current Ending Cash Position is $49.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oruka Therapeutics Business Description

Other Exchanges HQ1:Germany
Address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
14GF Score

Get the complete analysis for ORKA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$92.49
Price